Profit Share Territory was Ultragenyx Pharmaceutical’s largest region in fiscal 2025, bringing in $275.00M of $600.00M (46%).
| Geography | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profit Share Territory | — | $232.00M | $249.00M | $275.00M | ||||||
| North America | $281.09M | — | — | — | ||||||
| Latin America | $44.71M | $77.00M | $131.00M | $170.00M | ||||||
| Europe, Middle East, & Africa | $36.37M | $48.00M | $80.00M | $108.00M | ||||||
| Royalty Revenue In European Territory | — | $21.00M | $26.00M | $29.00M | ||||||
| European Territory | — | — | — | — | ||||||
| Europe | — | — | — | — | ||||||
| Asia-Pacific | $1.16M | $2.00M | $9.00M | $18.00M | ||||||
| All Other | — | — | — | — | ||||||
| United States Of America | — | — | — | — | ||||||
| Total | $363.33M | $380.00M | $495.00M | $600.00M |
Ultragenyx Pharmaceutical brought in $600.00M from its five regions in fiscal 2025, the year ended December 31, 2025. That was up 21.2% from $495.00M in fiscal 2024. Profit Share Territory was the largest at $275.00M (45.8%), ahead of Latin America at $170.00M (28.3%) and Europe, Middle East, & Africa at $108.00M (18.0%). The other two regions brought in $47.00M combined.
Compared with fiscal 2024, Asia-Pacific grew fastest, up 100.0% to $18.00M. Every region above 2% of revenue grew.
Ultragenyx Pharmaceutical began breaking out Profit Share Territory in fiscal 2023, when it brought in $232.00M. Ultragenyx Pharmaceutical stopped reporting North America as a separate region after fiscal 2022, when it brought in $281.09M.
Product Sales was Ultragenyx Pharmaceutical’s largest product and service line in fiscal 2025, bringing in $214.00M of $489.00M (44%).
| Product and Service | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Collaboration Revenue | $215.02M | $70.00M | — | — | ||||||
| Collaboration & License | $222.71M | $71.00M | — | — | ||||||
| Collaboration & Royalty | $215.02M | — | — | — | ||||||
| Royalty | — | $113.00M | $174.00M | $192.00M | ||||||
| Non-Cash Collaboration Royalty Revenue | $21.69M | — | — | — | ||||||
| Product Sales | $76.25M | $146.00M | $165.00M | $214.00M | ||||||
| Non-Cash Royalty Revenue | $21.69M | $49.00M | $75.00M | $83.00M | ||||||
| Total | $772.39M | $449.00M | $414.00M | $489.00M |
Ultragenyx Pharmaceutical brought in $489.00M from its three product and service lines in fiscal 2025, the year ended December 31, 2025. That is less than the $600.00M it reports by geography, so these lines do not cover all of its revenue. Product Sales was the largest at $214.00M (43.8%), ahead of Royalty at $192.00M (39.3%) and Non-Cash Royalty Revenue at $83.00M (17.0%).
Compared with fiscal 2024, Product Sales grew fastest, up 29.7% to $214.00M. Every line above 2% of revenue grew.
Ultragenyx Pharmaceutical began breaking out Royalty in fiscal 2023, when it brought in $113.00M. Ultragenyx Pharmaceutical stopped reporting Collaboration & Royalty ($215.02M in fiscal 2022), Collaboration & License ($71.00M in fiscal 2023), Collaboration Revenue ($70.00M in fiscal 2023) and one other as separate lines.
Kyowa Kirin Collaboration was Ultragenyx Pharmaceutical’s largest revenue line in fiscal 2025, bringing in $192.00M of $561.00M (34%).
| Type Of Arrangement | FY 2016 | FY 2019 | FY 2020 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|
| Kyowa Kirin Collaboration | $279.39M | $113.00M | $174.00M | $192.00M | |||
| Crysvita | $42.68M | $75.00M | $135.00M | $177.00M | |||
| Dojolvi | — | $71.00M | $88.00M | $96.00M | |||
| Evkeeza | — | $4.00M | $32.00M | $59.00M | |||
| Mepsevii | $20.64M | $30.00M | $30.00M | $37.00M | |||
| Total | $342.71M | $293.00M | $459.00M | $561.00M |
Ultragenyx Pharmaceutical brought in $561.00M from its five revenue lines in fiscal 2025, the year ended December 31, 2025. That is less than the $600.00M it reports by geography, so these revenue lines do not cover all of its revenue. Kyowa Kirin Collaboration was the largest at $192.00M (34.2%), ahead of Crysvita at $177.00M (31.6%) and Dojolvi at $96.00M (17.1%). The other two revenue lines brought in $96.00M combined.
Compared with fiscal 2024, Evkeeza grew fastest, up 84.4% to $59.00M. Every revenue line above 2% of revenue grew.
Ultragenyx Pharmaceutical began breaking out Evkeeza in fiscal 2023, when it brought in $4.00M.
Ultragenyx Pharmaceutical (RARE) reports its revenue by geography, by product and service and by type of arrangement. In fiscal 2025, Profit Share Territory was its largest region, bringing in $275.00M (45.8% of the total), followed by Latin America at $170.00M (28.3%).
Profit Share Territory was Ultragenyx Pharmaceutical's largest region in fiscal 2025, bringing in $275.00M, or 45.8% of the $600.00M total across its five regions.
Product Sales was Ultragenyx Pharmaceutical's largest product and service line in fiscal 2025, bringing in $214.00M, or 43.8% of the $489.00M total across its three product and service lines.
Kyowa Kirin Collaboration was Ultragenyx Pharmaceutical's largest revenue line in fiscal 2025, bringing in $192.00M, or 34.2% of the $561.00M total across its five revenue lines.
Among Ultragenyx Pharmaceutical's regions that make up at least 2% of revenue, Asia-Pacific grew fastest in fiscal 2025, up 100.0% from $9.00M to $18.00M.
Every figure comes from Ultragenyx Pharmaceutical's annual financial filings, as reported. Each line keeps the name Ultragenyx Pharmaceutical gives it, and years follow its fiscal calendar.
Ultragenyx Pharmaceutical's revenue by geography goes back to fiscal 2016, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.